"<10 minutes"@en . " "@en . . "Hexylcaine"@en . . "Symptoms of anesthetic overdose include headache, tinnitus, circumoral and tongue paresthesias, restlessness, talkativeness, facial twitching, convulsions, respiratory arrest, and cardiac depression"@en . . "approved"@en . "Humans and other mammals"@en . . . "U.S. Patent 2,486,374."@en . . . " "@en . . . . . "Cyclaine"@en . . . . . . . . . "Hexylcainum"@en . . . "Hexylcaine"@en . . . . . . . . . . . . "Hexyl caine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel."@en . "Hexilcaina"@en . . . . "withdrawn"@en . "Hexylcaine hydrochloride, also called cyclaine (Merck) or osmocaine, is a short-acting local anesthetic. It acts by inhibiting sodium channel conduction. Overdose can lead to headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function. Hexylcaine has been discontinued in the US market. "@en . . "Used as a local anesthetic for surface application, infiltration or nerve block"@en . . . . "532-77-4"@en .